Thus, although our expression analysis in human samples suggests strong ErbB3 expression in a significant proportion of ovarian cancers, a result that is also supported by previous findings29, ErbB3 expression alone may not represent a sufficient biomarker for treatment with anti-ErbB3 molecules. The gene discussed is ERBB3; the disease is ovarian cancer.